Physician profile
Edwin W Shearburn
NPI 1649262015
$430.16
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $169 · 2021: $45.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $161.89 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $42.50 | 2019 | |
| Endologix LLC | $40.05 | 2019 | |
| Davol INC. | $35.84 | 2019-2020 | |
| Ethicon US, LLC | $34.55 | 2020 | |
| Covidien LP | $21.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.64 | 2019 | |
| Intuitive Surgical, INC. | $18.28 | 2019 | |
| Merck Sharp & Dohme LLC | $17.03 | 2019 | |
| Baxter Healthcare | $14.20 | 2020 | |
| Focal Therapeutics, INC. | $12.04 | 2019 | |
| Smith+Nephew, INC. | $11.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Shearburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.